Platinum-based agents are important drugs or drug candidates for cancer chemotherapy. Traditional platinum drugs including the globally approved cisplatin, carboplatin and oxaliplatin are neutral platinum (II) complexes with two amine ligands and two additional ligands that can be aquated for further ...
Since the combination of platinum- and taxane-based agents are most common for the treatment of advanced-stage or recurrent endometrial cancer, this study explores, for the first time, the effect of PFAS exposure on the response of endometrial cancer cells to platinum-based chemotherapies. Carbopla...
Platinum-based drugs (cisplatin, carboplatin, and oxaliplatin) are widely used therapeutic agents for cancer treatment. Even though the platinum (Pt)-drugs are routinely used clinically, a clear picture of their distribution within tumor tissues is lacking. The current methods to image the ...
Platinum-based anti-cancer agents have been used for many years to treat many different types of cancer. However, the efficacy of these drugs is limited by serious side effects. One of the strategies to reduce the side effects is encapsulation of the drug in a lipid formulation. Recently, ...
Further studies may help elucidate the potential therapeutic benefits of these agents in managing steroid-resistant polyposis for patients suffering from olfactory dysfunction.CureusAditya MahadevanDepartment of Hematology and Oncology, University of California Irvine School of Medicine, Or...
J. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev. 116, 3436–3486 (2016). Article CAS PubMed PubMed Central Google Scholar Klein, A. V. & Hambley, T. W. Platinum drug distribution in cancer cells and tumors. ...
蔓越莓萃取果汁使得铂为基础(platinum-based)的药物对抗卵巢癌的能力增加六倍以上。继续阅读 ‘蔓越莓能增加癌症药物的治 … cranmax.wordpress.com|基于21个网页 3. 以含铂 治疗原则如小细胞肺癌一样,第一线治疗以含铂(platinum-based)的药物加上另一个化疗药物(如健择、汰癌胜、灭癌平、爱宁达 … ...
Owing to the availability of bio-reducing agents, mainly proteins, in all cell types, Pt(IV) prodrugs can be reduced to their cytotoxic active Pt(II) analogues in both cancer and normal cells. However, prolonged hydrolysis and less stability against bio-reducing agents are problems still to ...
Platinum-containing agents are not regarded as a standard for neoadjuvant therapy of TNBC, for several reasons. One reason is that given that the addition of platinum results in greater toxicity as seen in the previous studies, the clinical benefits of its use should be clear. It is also poss...
cells (Fig.4c). These data indicate that TAp73 influences NER in melanoma cells by increasing the level of NER-related proteins. In MAPKi-resistant melanoma cells, TAp73 expression is lower resulting in a reduced NER efficacy and an enhanced sensitivity towards platinum-based cytostatic agents. ...